Shunjie Guan

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

Yuao Zhu, Irina Yurgelonis, Stephen Noell et al. · Science Advances · 2024 · 45 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States

Arpana Khatri, Rajani Shelke, Shunjie Guan et al. · Human Gene Therapy · 2021 · 26 citations · Full text

Life Sciences, Immunology, Pharmacology +13

Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial

Edward A. Weinstein, Roger Paredes, Annie Gardner et al. · The Lancet Infectious Diseases · 2025 · 22 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or Mutations

Holly Soares, Mary Lynn Baniecki, Rhonda D. Cardin et al. · Research Square · 2022 · 13 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis

Stanley M. Cohen, Jean S. Beebe, Vishala Chindalore et al. · Arthritis Research & Therapy · 2024 · 13 citations · Full text

Medicine, Immunology, Pharmacology +17